Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M, Preuß C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, Wedeken K, Reis H, Herold T, Darwiche K, Aigner C, Stuschke M, Schildhaus HU, Schmid KW, Falk M, Heukamp L, Tiemann M, Griesinger F, Schuler M. Wiesweg M, et al. Among authors: griesinger f. Eur J Cancer. 2021 May;149:211-221. doi: 10.1016/j.ejca.2021.02.036. Epub 2021 Apr 16. Eur J Cancer. 2021. PMID: 33872981
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Sebastian M, Eberhardt WEE, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K, Alt J, Schütte W, Büttner R, Heukamp LC, Stenzinger A, Jänicke M, Fleitz A, Zacharias S, Dille S, Hipper A, Sandberg M, Weichert W, Groschek M, von der Heyde E, Rauh J, Dechow T, Thomas M, Griesinger F; CRISP Registry Group. Sebastian M, et al. Among authors: griesinger f. Lung Cancer. 2021 Apr;154:51-61. doi: 10.1016/j.lungcan.2021.02.005. Epub 2021 Feb 13. Lung Cancer. 2021. PMID: 33611226 Free article.
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
Christopoulos P, Kluck K, Kirchner M, Lüders H, Roeper J, Falkenstern-Ge RF, Szewczyk M, Sticht F, Saalfeld FC, Wesseler C, Hackanson B, Dintner S, Faehling M, Kuon J, Janning M, Kauffmann-Guerrero D, Kazdal D, Kurz S, Eichhorn F, Bozorgmehr F, Shah R, Tufman A, Wermke M, Loges S, Brueckl WM, Schulz C, Misch D, Frost N, Kollmeier J, Reck M, Griesinger F, Grohé C, Hong JL, Lin HM, Budczies J, Stenzinger A, Thomas M. Christopoulos P, et al. Among authors: griesinger f. Eur J Cancer. 2022 Jul;170:106-118. doi: 10.1016/j.ejca.2022.04.020. Epub 2022 May 20. Eur J Cancer. 2022. PMID: 35598358
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC.
Roeper J, Falk M, Chalaris-Rißmann A, Lueers AC, Ramdani H, Wedeken K, Stropiep U, Diehl L, Tiemann M, Heukamp LC, Otto-Sobotka F, Griesinger F. Roeper J, et al. Among authors: griesinger f. Oncotarget. 2020 Jan 21;11(3):250-264. doi: 10.18632/oncotarget.27430. eCollection 2020 Jan 21. Oncotarget. 2020. PMID: 32076486 Free PMC article.
Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
Ramdani HO, Falk M, Heukamp LC, Schatz S, Tiemann M, Wesseler C, Diehl L, Schuuring E, Groen HJM, Griesinger F. Ramdani HO, et al. Among authors: griesinger f. Pathol Res Pract. 2021 Nov;227:153651. doi: 10.1016/j.prp.2021.153651. Epub 2021 Oct 12. Pathol Res Pract. 2021. PMID: 34673351 Free article.
220 results